AMANDA DEVANEY: Open Payments
NPI 1649933987 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,018 in 55 payments from 15 companies in 2025. Trend: 2023 $1,631 · 2024 $1,801 · 2025 $1,018
Food & beverage: $1,018
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $142 |
| GENZYME CORPORATION | 4 | $118 |
| Phathom Pharmaceuticals, Inc. | 7 | $105 |
| Celltrion USA Inc. | 3 | $78 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $71 |
| PFIZER INC. | 3 | $67 |
| Lilly USA, LLC | 2 | $49 |
| Janssen Biotech, Inc. | 2 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
Products named: VOQUEZNA, DUPIXENT, RINVOQ, VEGZELMA, ENTYVIO, EOHILIA, XELJANZ, LINZESS.
Industry payments across VA — which companies pay providers there.
